Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ADVOS-COVID-19

Financiado

Cerrado

Increasing Survival of Patients with Severe SARS CoV 2 Infection and or Multi Or...

Increasing Survival of Patients with Severe SARS CoV 2 Infection and or Multi Organ Failure by up to 30 with ADVOS ADVanced Organ Support ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF). First published clinical data show that ADVOS improves survival by u... ver más

30/06/2023

ADVITOS GmbH

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

ADVITOS GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-06-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 69% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

ADVITOS GmbH

951.95K€ | Lider

COMPANIA ALIMENTARIA COALA

194.26K€ | Participante

ENERGESA

339.82K€ | Participante

OVINOTECNIA MANCHEGA

340.16K€ | Participante

Proyectos interesantes

PyXy.AI

Medical Technol...

Artificial Inte...

7M€ Cerrado

STRATIFYHF

Medical Technol...

Artificial Inte...

4M€ Cerrado

CIRDinnova

Medical Technol...

Data Science

3M€ Cerrado

ENVISION

Medical Technol...

Data Science

6M€ Cerrado

CoronAI

Medical Technol...

Artificial Inte...

3M€ Cerrado

ESCORT

Medical Technol...

Software

5M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 35 meses Fecha Inicio: 2020-07-27
Fecha Fin: 2023-06-30

Líder del proyecto

ADVITOS GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF). First published clinical data show that ADVOS improves survival by up to 30% in critically ill patients on intensive care. The first COVID-19 patient with MOF is being treated with ADVOS in Germany at present with promising results. ADVITOS is a SME instrument Phase 2 beneficiary: ADVOS 880349 for device usability improvement, IoT integration, and market expansion (2.3m€ grant). Following the urgent EU call for corona solutions, we apply now for the blended finance option to speed up device production and installation in Germany and other EU countries. The applied funding and equity is necessary in therapy application, service and sales resources as well as accelerated clinical evidence for medical indication guidance. Integrating fluid-based blood oxygenation for comprehensive lung support and AI/digital capabilities will achieve additional therapy and outcome improvement. Each year, 60% of intensive care patients - 500,000 individuals in Western Europe and the US - die of MOF. The coronavirus outbreak will further increase this number dramatically as COVID-19 often leads to MOF. The innovative ADVOS therapy has the potential to revolutionize intensive care therapy of patients worldwide, as it is the 1st and only blood purification therapy combining liver, lung, kidney support and direct blood pH correction in 1 device (technology leader in removal of liver toxins and fast extracorporeal blood pH correction). It will help to save lives in the current Corona crisis. The ADVOS therapy is low-invasive as standard hemodialysis, so it can support by far more ICU patients than other devices (that have a higher risk profile). This relates especially to the removal of CO2 (by ADVOS) which relieves the lung and reduces the need/invasiveness of ventilation.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores